Incyte Corporation Company Profile

Incyte Corporation

Route 141 & Henry Clay Road
Building E336
Wilmington, DE 19880
United States
Tel: 1/302.498.6700
URL: http://www.incyte.com
Formerly known as:
Incyte Genomics Inc.
Primary Symbol & Exchange:
INCY - Common Stock - NASDAQ
Industry:
Biotechnology
+  SIC Industry Code:
+  NAICS Industry Code:
Mergers & Acquisitions:
Incyte Corporation Mergers and Acquisitions
Thomson Reuters Business Description:
Incyte Corporation (Incyte) is a drug discovery and development company focused on developing small molecule drugs to treat serious unmet medical needs. The Company has a pipeline with programs focused primarily in the areas of oncology and inflammation. Its priority programs involve its janus kinase (JAK) inhibitors, which include oral INCB18424 for hematologic and oncology indications, and oral INCB28050 for chronic inflammatory and autoimmune diseases. Oral INCB18424 is in Phase III development as a treatment for myelofibrosis, the advanced of the myeloproliferative neoplasms and Phase II development for two of the other myeloproliferative neoplasms, polycythemia vera and essential thrombocythemia. Oral INCB28050 is in Phase II development for rheumatoid arthritis. The Company’s pipeline includes compounds in various stages of development, primarily in the areas of oncology and inflammation.
Research Alerts: Incyte Corporation RSS Feed Subscribe with My Yahoo!
Receive alerts on the latest reports on Incyte Corporation

Subscribe to Research Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.

Premium Content Results:







Search for more premium content on Incyte Corporation